-Reuters
Cellectar Bio’s Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer
Cellectar Biosciences Inc (NASDAQ:CLRB) has completed part A portion of a safety and tolerability study of iopofosine I-131 (iopofosine) in combination…